Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $8.5 in the prior trading day, Terns Pharmaceuticals Inc (NASDAQ: TERN) closed at $8.61, up 1.29%. In other words, the price has increased by $1.29 from its previous closing price. On the day, 0.83 million shares were traded. TERN stock price reached its highest trading level at $9.0316 during the session, while it also had its lowest trading level at $8.55.
Ratios:
Our goal is to gain a better understanding of TERN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 24.70 and its Current Ratio is at 24.70. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Truist on October 15, 2025, initiated with a Buy rating and assigned the stock a target price of $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 01 ’25 when Kuriakose Emil sold 944 shares for $7.85 per share. The transaction valued at 7,407 led to the insider holds 51,520 shares of the business.
Kuriakose Emil sold 853 shares of TERN for $3,640 on Jul 01 ’25. The Chief Medical Officer now owns 52,464 shares after completing the transaction at $4.27 per share. On Jun 27 ’25, another insider, Gengos Andrew, who serves as the Chief Financial Officer of the company, bought 10,000 shares for $3.93 each. As a result, the insider paid 39,283 and bolstered with 25,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TERN now has a Market Capitalization of 753470080 and an Enterprise Value of 439158112.
Stock Price History:
The Beta on a monthly basis for TERN is -0.05, which has changed by 0.16194332 over the last 52 weeks, in comparison to a change of 0.13033986 over the same period for the S&P500. Over the past 52 weeks, TERN has reached a high of $8.78, while it has fallen to a 52-week low of $1.87. The 50-Day Moving Average of the stock is 16.70%, while the 200-Day Moving Average is calculated to be 79.91%.
Shares Statistics:
The stock has traded on average 1.15M shares per day over the past 3-months and 1356670 shares per day over the last 10 days, according to various share statistics. A total of 87.47M shares are outstanding, with a floating share count of 69.58M. Insiders hold about 20.49% of the company’s shares, while institutions hold 82.90% stake in the company. Shares short for TERN as of 1759190400 were 8226341 with a Short Ratio of 7.18, compared to 1756425600 on 7857238. Therefore, it implies a Short% of Shares Outstanding of 8226341 and a Short% of Float of 9.4.
Earnings Estimates
The market rating for Terns Pharmaceuticals Inc (TERN) is a result of the insights provided by 9.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.3, with high estimates of -$0.24 and low estimates of -$0.38.
Analysts are recommending an EPS of between -$1.06 and -$1.34 for the fiscal current year, implying an average EPS of -$1.15. EPS for the following year is -$1.22, with 9.0 analysts recommending between -$0.75 and -$1.49.
